Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
It may not be something you like to talk about, but if you have gastrointestinal (GI) problems, your symptoms may be far more ...
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.
The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.
An international study led by the University of Oulu and Oulu University Hospital has identified six genetic regions ...
Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...
Probiotics may help with many health conditions. Although they're generally safe, it's important to talk with your doctor ...
An international study led by the University of Oulu and Oulu University Hospital has identified six genetic regions ...
A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as ...
Doctors believe new test could lead to earlier diagnoses and more effective treatment for thousands of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback